{"pmid":32386744,"title":"Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?","text":["Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?","Med Clin (Barc)","Lasheras, Isabel","Santabarbara, Javier","32386744"],"journal":"Med Clin (Barc)","authors":["Lasheras, Isabel","Santabarbara, Javier"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32386744","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.medcli.2020.04.004","topics":["Treatment"],"weight":1,"_version_":1666428892662988800,"score":9.490897,"similar":[{"pmid":32407539,"title":"Clinical trials for Covid-19: can we better use the short window of opportunity?","text":["Clinical trials for Covid-19: can we better use the short window of opportunity?","The scientific community has risen to the Covid-19 challenge, coming up with an impressive list of candidate drugs and vaccines targeting an array of pharmacological and immunological mechanisms. Yet, generating clinical evidence of efficacy and safety of these candidate treatments may be frustrated by the absence of comprehensive trial coordination mechanisms. Many small stand-alone trials and observational studies of single-agent interventions are currently running or in planning; many of these will likely not deliver robust results that could support regulatory and patient-level treatment decisions. We here discuss actions that all stakeholders in the clinical trial ecosystem need to take to ensure that the window of opportunity during this pandemic will not shut, both for patients in need of treatment and for researchers to conduct decision-relevant clinical trials.","Clin Pharmacol Ther","Eichler, Hans-Georg","Cavaleri, Marco","Enzmann, Harald","Scotti, Francesca","Sepodes, Bruno","Sweeney, Fergus","Vamvakas, Spiros","Rasi, Guido","32407539"],"abstract":["The scientific community has risen to the Covid-19 challenge, coming up with an impressive list of candidate drugs and vaccines targeting an array of pharmacological and immunological mechanisms. Yet, generating clinical evidence of efficacy and safety of these candidate treatments may be frustrated by the absence of comprehensive trial coordination mechanisms. Many small stand-alone trials and observational studies of single-agent interventions are currently running or in planning; many of these will likely not deliver robust results that could support regulatory and patient-level treatment decisions. We here discuss actions that all stakeholders in the clinical trial ecosystem need to take to ensure that the window of opportunity during this pandemic will not shut, both for patients in need of treatment and for researchers to conduct decision-relevant clinical trials."],"journal":"Clin Pharmacol Ther","authors":["Eichler, Hans-Georg","Cavaleri, Marco","Enzmann, Harald","Scotti, Francesca","Sepodes, Bruno","Sweeney, Fergus","Vamvakas, Spiros","Rasi, Guido"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407539","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1002/cpt.1891","topics":["Treatment"],"weight":1,"_version_":1666802845546971138,"score":54.396706},{"pmid":32400882,"title":"COVID-19 and telehealth: a window of opportunity and its challenges.","text":["COVID-19 and telehealth: a window of opportunity and its challenges.","Swiss Med Wkly","Nittas, Vasileios","von Wyl, Viktor","32400882"],"journal":"Swiss Med Wkly","authors":["Nittas, Vasileios","von Wyl, Viktor"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32400882","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.4414/smw.2020.20284","weight":0,"_version_":1666714494707957760,"score":51.06523},{"pmid":32351873,"pmcid":"PMC7189021","title":"Will the antimalarial drug take over to combat COVID-19?","text":["Will the antimalarial drug take over to combat COVID-19?","Background: China has been fighting the epidemic of pneumonia-like diseases first detected for over a month in the city of Wuhan in December 2019. The disease epidemic is caused by a novel coronavirus, called COVID-19, which has now infected more than 700,000 people worldwide. With a death toll approaching that of China's SARS-CoV outbreak in 2002 and 2003, 2019-nCoV has contributed to an international emergency in public health, placing all health organizations on high alert. Such large numbers of infected and deceased people require an urgent need for reliable, inexpensive, and cheap drugs to control and reduce the outbreak. Objective: To systematically review and evaluate the pattern of COVID-19 and the treatment plans. Methods: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The articles were searched from databases like PubMed, the Cochrane Library, ScienceDirect, and the Health Research and Development Information Network (HERDIN) combining MeSH and free-text terms. Results: This analysis highlights the agent of COVID-19 and the possible transmission. The current research taking place to overcome this complex disease and the urgent need to develop improved therapeutics are also discussed. Conclusion: Herein, we present an epidemiological overview of the currently available information on the treatment claimed to have helped to bring the situation under control.","Z Gesundh Wiss","T K, Sivabakya","G, Srinivas","32351873"],"abstract":["Background: China has been fighting the epidemic of pneumonia-like diseases first detected for over a month in the city of Wuhan in December 2019. The disease epidemic is caused by a novel coronavirus, called COVID-19, which has now infected more than 700,000 people worldwide. With a death toll approaching that of China's SARS-CoV outbreak in 2002 and 2003, 2019-nCoV has contributed to an international emergency in public health, placing all health organizations on high alert. Such large numbers of infected and deceased people require an urgent need for reliable, inexpensive, and cheap drugs to control and reduce the outbreak. Objective: To systematically review and evaluate the pattern of COVID-19 and the treatment plans. Methods: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The articles were searched from databases like PubMed, the Cochrane Library, ScienceDirect, and the Health Research and Development Information Network (HERDIN) combining MeSH and free-text terms. Results: This analysis highlights the agent of COVID-19 and the possible transmission. The current research taking place to overcome this complex disease and the urgent need to develop improved therapeutics are also discussed. Conclusion: Herein, we present an epidemiological overview of the currently available information on the treatment claimed to have helped to bring the situation under control."],"journal":"Z Gesundh Wiss","authors":["T K, Sivabakya","G, Srinivas"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32351873","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1007/s10389-020-01293-0","keywords":["covid-19","china","chloroquine","hydroxychloroquine","outbreak","wuhan"],"locations":["China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138495581683713,"score":44.59207},{"pmid":32478396,"title":"Lockdown to contain COVID-19 is a window of opportunity to prevent the second wave.","text":["Lockdown to contain COVID-19 is a window of opportunity to prevent the second wave.","J Travel Med","Wilder-Smith, Annelies","Bar-Yam, Yaneer","Fisher, Dale","32478396"],"journal":"J Travel Med","authors":["Wilder-Smith, Annelies","Bar-Yam, Yaneer","Fisher, Dale"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478396","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1093/jtm/taaa091","keywords":["sars-cov-2","contact tracing","isolation","mobility","non-pharmaceutical intervention","quarantine","travel restrictions"],"topics":["Prevention"],"weight":1,"_version_":1668532089543196673,"score":43.561333},{"pmid":32424028,"title":"Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?","text":["Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?","Ann Rheum Dis","Erre, Gian Luca","Ferraccioli, Edoardo Sean","Piga, Matteo","Mangoni, Arduino","Passiu, Giuseppe","Gremese, Elisa","Ferraccioli, Gianfranco","32424028"],"journal":"Ann Rheum Dis","authors":["Erre, Gian Luca","Ferraccioli, Edoardo Sean","Piga, Matteo","Mangoni, Arduino","Passiu, Giuseppe","Gremese, Elisa","Ferraccioli, Gianfranco"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424028","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/annrheumdis-2020-217828","keywords":["antirheumatic agents","cardiovascular diseases","hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1667352728878186496,"score":42.7838}]}